Intervention not reported
Total number of withdrawals · children with chronic asthma
The intervention may leads to lower total number of withdrawals (low certainty).
1 finding from 1 review
Intervention not reported
Change in FEV1 (L) at endpoint · children with chronic asthma
1 finding from 1 review
Intervention not reported
Change in morning PEF (L/min) at endpoint · children with chronic asthma
1 finding from 1 review
Intervention not reported
Total number of adverse events · children with chronic asthma
The intervention showed no clear difference in total number of adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of participants with exacerbations requiring systemic steroids · children with chronic asthma
The intervention showed no clear difference in number of participants with exacerbations requiring systemic steroids (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of participants with exacerbations requiring hospitalisation · children with chronic asthma
The intervention showed no clear difference in number of participants with exacerbations requiring hospitalisation (moderate certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in exacerbation: systemic corticosteroids 17 weeks compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Asthma control · adults with asthma well controlled on LABA and ICS
1 finding from 1 review
Serious adverse events 17 weeks · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in serious adverse events 17 weeks compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Asthma‐related quality of life (MCID) · adults with asthma well controlled on LABA and ICS
1 finding from 1 review
Exacerbation: hospital 17 weeks · adults with asthma well controlled on LABA and ICS
1 finding from 1 review
Adverse events (all) · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in adverse events (all) compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Withdrawal (all‐cause) · adults with asthma well controlled on LABA and ICS
Stopping LABA probably leads to higher withdrawal (all) compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Number of participants with exacerbations requiring systemic steroids · patients with chronic asthma
LABA + ICS leads to lower participants with one or more exacerbations requiring systemic… compared with LTRA + ICS (high certainty).
1 finding from 1 review
Change from baseline in morning PEFR (L/min) Duration of trials: 8 to 13 weeks · patients with chronic asthma
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · patients with chronic asthma
1 finding from 1 review
Rescue‐free days: % change from baseline · patients with chronic asthma
1 finding from 1 review
Use of rescue medication · patients with chronic asthma
1 finding from 1 review
Withdrawals due to any reason · patients with chronic asthma
LABA + ICS probably leads to lower withdrawals for any reason compared with LTRA + ICS (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic asthma
LABA + ICS showed no clear difference in serious adverse events compared with LTRA + ICS (moderate certainty).
1 finding from 1 review